Human urinary bladder carcinoma marker AG-CD71 and antibody ABC71 and application thereof

An AG-CD71, bladder cancer technology, applied in the field of tumor immunology, can solve the problems of high cost of urethral cystoscopy, bleeding, inconvenient operation, etc.

Active Publication Date: 2018-01-12
北京中科健兰集团有限公司
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the diagnosis and follow-up of bladder cancer mainly rely on urethral cystoscopy, but invasive urethral cystosc...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human urinary bladder carcinoma marker AG-CD71 and antibody ABC71 and application thereof
  • Human urinary bladder carcinoma marker AG-CD71 and antibody ABC71 and application thereof
  • Human urinary bladder carcinoma marker AG-CD71 and antibody ABC71 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Preparation and purification of ABC71 monoclonal antibody:

[0031] (1) Preparation of hybridoma cells

[0032] 1) Animal immunization and cell culture: Homogenize human bladder cancer tissue to extract total protein, immunize Balb / C mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), and use 50ug of total protein per mouse. Dose for intraperitoneal immunization. Mice were re-immunized every two weeks. After the titer of the mouse serum reaches the requirement, the immunization is boosted again. After 3 days, the spleen of the mouse is taken to prepare a spleen cell suspension for cell fusion. Mouse myeloma cells Sp2 / 0 (ATCC CRL-1772) were revived and selected with 8-AG (8-azaguanine) to maintain the sensitivity of the cells to HAT.

[0033] 2) Cell fusion: Fusion the splenocyte suspension prepared in step 1) with myeloma cells. For specific methods, refer to "Guidelines for Experimental Immunology" ((USA) J.E. Science Root (USA) D.H...

Embodiment 2

[0041] Identification of ABC71 monoclonal antibodies:

[0042] Using the ABC71 monoclonal antibody prepared in Example 1 to carry out immunohistochemistry to human bladder cancer tissue and human normal bladder tissue section, the results are as follows figure 1 , 2 shown. The results showed that the human bladder cancer tissue showed positive reaction after ABC71 monoclonal antibody immunohistochemical staining (such as figure 1 shown), while normal human bladder tissue showed a negative reaction after ABC71 monoclonal antibody immunohistochemical staining (such as figure 2 shown).

[0043] Using the ABC71 monoclonal antibody prepared in Example 1, human bladder cancer tissue and human normal bladder tissue were detected by immunohistochemistry, and the results are shown in Table 1. The results showed that the ABC71 antibody had a strong positive reaction with human bladder cancer tissue, but had no cross-reaction with normal human bladder tissue.

[0044] Table 1. Immu...

Embodiment 3

[0047] Preparation of AG-CD71 antigen:

[0048] 1) Total protein extraction: Grind 100mg of human bladder cancer tissue into a homogenate, add 2ml of three decontamination lysate, lyse at 4°C for 10 minutes, centrifuge at 12000rpm for 20 minutes, and take the supernatant, which is the total protein of human bladder cancer tissue.

[0049] 2) Immunoprecipitation: Add 50ug of ABC71 monoclonal antibody and incubate at 4°C for 2h.

[0050] 3) Antigen identification: add 50ul Protein G beads and incubate at 4°C for 2h. The beads were washed with PBS, and then the beads were eluted with 0.2 mol / L glycine-HCl solution (pH2.8) for mass spectrometry analysis. The mass spectrometry results are shown in Table 2. The results of mass spectrometry showed that the antigen of ABC71 was the transferrin receptor TFRC. After analyzing the sugar chip data of ABC71 monoclonal antibody (such as image 3 (shown) found that the antigenic epitope recognized by the ABC71 monoclonal antibody is the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention mainly belongs to the technical field of tumor immunology, and particularly relates to a human urinary bladder carcinoma marker AG-CD71 and a monoclonal antibody ABC71 for preventing AG-CD71. The human urinary bladder carcinoma marker AG-CD71 provided by the invention is an abnormal glycosylated transferrin receptor TFRC; the abnormal glycosylated transferrin receptor TFRC refers tothat the TFRC carriers a saccharide structure Fucal-4(GlcNAcb1-3) as an epitope; the invention provides an antibody for the human urinary bladder carcinoma marker AG-CD71; the antibody is a specific monoclonal antibody ABC71 for preventing the human urinary bladder carcinoma marker AG-CD71; the monoclonal antibody is secreted from a hybridoma cell strain of which the preservation number is CGMCC No.14312. Cell and histology levels show that the ABC71 is capable of specifically recognizing human urinary bladder carcinoma cells and human urinary bladder carcinoma tissue. The monoclonal antibodyABC71 for preventing the human urinary bladder carcinoma has an intense positive reaction with human urinary bladder carcinoma tissue and has a negative reaction with normal human urinary bladder tissue.

Description

technical field [0001] The invention mainly belongs to the technical field of tumor immunology, and specifically relates to a novel bladder cancer marker AG-CD71 and the anti-AG-CD71 monoclonal antibody ABC71. Cellular and histological levels prove that: ABC71 specifically recognizes human bladder cancer cells and human bladder cancer tissues. The invention also relates to a method for immunocytochemical detection of human bladder cancer. The antigen detected by the detection method is the novel human bladder cancer marker AG-CD71 in the present invention, and the detection antibody is the monoclonal antibody ABC71 against human bladder cancer AG-CD71 in the present invention. Background technique [0002] Bladder cancer refers to malignant tumors that occur on the bladder mucosa. It is the most common malignant tumor of the urinary system and one of the top ten common tumors in the whole body. It accounts for the first place in the incidence of genitourinary system tumors ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/705C12N5/20C07K16/30C07K16/28G01N33/68G01N33/574A61K39/395A61K47/68A61P35/00C12R1/91
CPCA61P35/00A61K38/00A61K47/6861C07K16/3038G01N33/57407G01N33/57484G01N2333/70582C07K14/70582A61K47/68A61K2039/505C07K16/2881C07K16/30G01N33/574
Inventor 李翀
Owner 北京中科健兰集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap